Posts

Barcelona Liver Bioservices (BLB) announced today the presentation of an original communication at the annual meeting of the American Association for the Study of the Liver (AASLD), held as The Liver Meeting Digitial Experience.

Poster #1914 “GTX-011 improves portal hypertension, liver fibrosis and endothelial dysfunction in a rat model of non-alcoholic steatohepatitis” will be presented by Zoe Boyer, Senior Associate Scientist at BLB. The study, fruit of the collaboration between BLB and GAT Therapeutics, describes for the first time the effects of the novel non-steroidal modulator of 3C nuclear receptors GTX-011 in a pre-clinical model of NASH. Results of the study show that rats receiving GTX-011 exhibited significant improvement in portal hypertension, considered the most detrimental complication of advanced liver disease. Underlying mechanisms of this hemodynamic improvement included amelioration of liver sinusoidal endothelial cells (showing improved vasodilator and anti-inflammatory mediators), together with amelioration in the metabolic profile (reduced FFA and insulin resistance). Importantly, GTX-011 administration led to partial de-activation of hepatic stellate cells. “We are glad to describe in detail the benefits of this compound in a pre-clinical model of NASH that particularly recapitulates the main pathophysiological features and transcriptome de-regulations of the human disease”, stated Dr Gracia-Sancho, co-founder and CSO of BLB.

Barcelona Liver Bioservices is a CRO focused on the design and development of pre-clinical research in the field of Hepatology. For more information about the company, our publications and available research services please visit www.liver.barcelona